Author: Ravi Shankar

LONDON, Oct. 21, 2026 (GLOBE NEWSWIRE) — Apollo, a Skyward Group company (Nasdaq: SKWD), an innovation-inspired insurance platform, today announced it has partnered with Generali to launch a new platform partner syndicate for which it will act as managing agent. Red Bridge Syndicate 2031 has received “in-principle” approval from Lloyd’s and is expected to begin underwriting on 1 January 2027.

Red Bridge will provide an opportunity for Lloyd’s members to share in Generali’s highly diversified outward reinsurance programme that covers multiple lines of business across Europe. For Generali, the syndicate secures access to new sources of capital to support its growth aspirations.

Apollo adds Red Bridge to its growing portfolio of platform partner syndicates at Lloyd’s, further demonstrating the value of Apollo’s differentiated third party syndicate management offering. Through this model, partners benefit from Apollo’s expertise and proven track record of building innovative and profitable underwriting businesses. In addition to traditional managing agency services, Apollo’s Platform Partners benefit from Apollo’s underwriting expertise, bespoke captive syndicate solutions, and access to potential reinsurance and capital opportunities, creating a more comprehensive and differentiated partnership.

Andrew Gray, Director of Partner Syndicates at Apollo, said: “We are delighted to be partnering with Generali in the launch of the Red Bridge syndicate, which brings together two incredible insurance institutions to create an innovative risk transfer solution. We are very proud to have been entrusted with this wonderful opportunity to use our unique expertise to help Generali build a successful and sustainable syndicate for the long term.”

Matthew Newman, PPS development director, at Apollo, said: “Our strategy is to partner with strong businesses and help them build something that lasts at Lloyd’s. Generali is exactly that kind of partner. Apollo has demonstrated existing capabilities to service and operate similar risk transfer opportunities to a diversified capital and investor base, so we know what it takes, and we’re proud Generali has chosen us to build Red Bridge with them.”

Red Bridge will begin underwriting in January 2027. This new partnership brings Apollo’s total number of syndicates under management to 11, further expanding its Platform Partner business and generating additional fee-based revenue for Skyward Group.

About Apollo

Apollo, a Skyward Group company, is an innovation inspired insurance platform operating at Lloyd’s of London, offering data-driven and creative solutions to a wide variety of risks.

The business provides high-quality products and services to clients, and capital partners, enabling a resilient and sustainable world.

Apollo offers products across Property, Casualty, Marine, Energy & Transportation, Specialty, Reinsurance, as well as Smart Follow and digital & embedded risk programs.

Apollo’s experience and unique ecosystem give Platform Partners the best chance of success through the Lloyd’s new entrant process to the delivery of their long-term strategy. For more information about Apollo, please visit apollounderwriting.com.

About Skyward Group

Skyward Group is the holding company brand for its U.S. and U.K. businesses, Skyward Specialty Insurance Group, Inc.® and Apollo, respectively, delivering a comprehensive suite of specialized insurance solutions across global specialty property and casualty markets. Focused on the specialty industry’s most niche, complex risks of today and the emerging challenges of tomorrow, Skyward Group leverages the forward-looking insight and disciplined execution of each organization to drive sustainable growth and long-term value for its shareholders, distribution partners and other stakeholders. For more information about Skyward Group, Skyward Specialty and Apollo, please visit skywardgroup.com.

About the Generali Group

Generali is one of the largest integrated insurance and asset management groups worldwide, with a total premium income of € 98.1 billion and € 900 billion AUM in 2025. Established in 1831, with over 88,000 employees and 163,000 advisors serving 75 million customers, the Group has a leading position in Europe and a growing presence in Asia and America. At the heart of Generali’s strategy is its Lifetime Partner commitment to customers, achieved through innovative and personalised solutions, best-in-class customer experience and its digitalised global distribution capabilities. The Group has fully embedded sustainability into all strategic choices, with the aim to create value for all stakeholders while building a fairer and more resilient society.

MEDIA ENQUIRIES

Haggie Partners

Peter Rigby, Caroline Klein, Ben Rothschild, Finlay Gardner, Ellie Livingstone
Email: Apollo@haggiepartners.com
Tel: + 44 20 7562 4444

Skyward Group

Haley Doughty
Skyward Specialty Insurance Group
hdoughty@skywardinsurance.com
713-935-4944

Investor Contact

Jordan Arnold, Vice President, Investor Relations
Skyward Group 
JArnold@skywardinsurance.com
346.215.0250

Company building on new revenue-generating relationships with potential to substantially expand its business

SHOREHAM, N.Y., Oct. 21, 2026 (GLOBE NEWSWIRE) — Mobiquity Technologies, Inc. (OTCQB: MOBQ) (“Mobiquity” or the “Company”), an AI-powered advertising technology and customer acquisition company, today highlighted several emerging business opportunities that management believes could significantly expand the Company’s revenue base and accelerate long-term growth.

The digital advertising industry is undergoing a fundamental transformation as artificial intelligence reshapes how businesses identify, engage and acquire customers. Mobiquity has already transitioned beyond traditional programmatic advertising through its GrowthOS™ platform, integrating AI-powered customer acquisition, audience intelligence and marketing automation to compete in this evolving marketplace.

“We believe Mobiquity is entering a potentially pivotal stage in its development,” said Dean Julia, Chief Executive Officer. “We are generating revenue from several new commercial relationships and are actively pursuing opportunities to expand them substantially. What makes these opportunities particularly compelling is that several involve established businesses with existing customers, revenue streams and infrastructure, creating the potential to scale more rapidly.”

The Company’s expanding initiatives span digital advertising, music and entertainment, agency services, e-commerce and AI-driven customer acquisition. Management is exploring strategic combinations, deeper commercial relationships and additional revenue channels that could leverage GrowthOS across established customer bases.

Management believes these opportunities, individually and collectively, have the potential to materially transform Mobiquity’s revenue profile and market position.

“Unlike opportunities that require building a business from the ground up, we are working with established commercial relationships that are already producing revenue,” Julia continued. “By combining these relationships with GrowthOS, we see a path toward significantly greater scale, recurring revenue and operating efficiencies.”

Certain opportunities remain subject to further agreements, execution milestones and, where applicable, additional financing, and their ultimate outcomes cannot be guaranteed.

“Our focus is on converting the momentum we are seeing today into sustainable, meaningful growth,” Julia concluded. “We believe the foundation is in place, the opportunities are substantial, and the next phase of Mobiquity’s development could be its most significant yet.”

About Mobiquity Technologies, Inc.

Mobiquity Technologies, Inc. (OTCQB: MOBQ) is a technology company focused on helping organizations identify, engage, convert, and retain customers through intelligent automation. Through its GrowthOS platform, the Company combines customer intelligence, AI-driven decisioning, predictive analytics, and omnichannel execution to help businesses improve customer acquisition outcomes and operational efficiency.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including the Private Securities Litigation Reform Act of 1995, to the extent applicable. Such statements include expectations regarding Mobiquity’s GrowthOS platform, AI initiatives, strategic relationships, potential acquisitions, revenue opportunities, financing and future growth. These statements are subject to significant risks and uncertainties, including the Company’s limited financial resources, operating losses, liquidity constraints, ability to obtain additional financing, potential shareholder dilution, customer adoption, technology commercialization and ability to achieve sustainable profitability. Certain opportunities remain preliminary, are not subject to definitive agreements and may require substantial additional capital. Existing revenue-generating relationships do not guarantee future revenue growth, and there can be no assurance that anticipated transactions will close, financing will be available on acceptable terms, or projected business opportunities will materialize. Failure to secure sufficient capital could require the Company to significantly curtail operations, restructure or discontinue portions of its business, or cease operations entirely. Actual results may differ materially from management’s expectations. Additional risks are described in the Company’s filings with the Securities and Exchange Commission at www.sec.gov. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them except as required by law.

MEDIA CONTACTS

Mobiquity Technologies
Deep Katyal
info@mobiquitytechnologies.com
516-246-9422

After a custodianship that cleared legacy liabilities and restored the Company to good standing, GBHL plans to combine with PYX Wallets, a developer of titanium smart wallets that combine physical card security, fingerprint access, connected app controls and offline crypto protection

LAS VEGAS, Oct. 21, 2026 (GLOBE NEWSWIRE) — Global Entertainment Holdings, Inc. (OTC: GBHL) (“GBHL” or the “Company”) today announced that on October 16, 2026, it signed a binding letter of intent (the “Agreement”) with PYX Wallets Inc. (“PYX”). Under the Agreement, PYX would acquire voting control of GBHL and contribute its business to the Company. The parties expect to sign definitive agreements and complete the change of control on or before October 30, 2026.

About the PYX Platform

Wallets protect what people carry every day, but they have changed little in decades. PYX is developing titanium smart wallets that combine physical card protection with fingerprint access and connected controls through mobile and desktop apps. PyX Core is designed to protect everyday cards, with GPS tracking and RFID/NFC shielding. PyX Vault combines Core’s connected security features with a hardware crypto wallet, bringing physical cards and crypto cold storage together in one device. Planned features include the ability to:

• Unlock the wallet using the biometric fingerprint sensor located on the side or through the PYX app, and manage multiple saved fingerprints through the app.
• Locate the wallet with built-in GPS, activate Lost Mode through the PYX app if the wallet is lost or goes missing, and check battery level in the app. Built-in RFID/NFC shielding helps protect cards from unauthorized scans.
• Store crypto private keys offline with PyX Vault and review the amount and recipient on its integrated display before approving transactions on the wallet. Planned Vault app features include buying, sending and receiving crypto.

PyX Core and PyX Vault are currently in development, and their final design, features and functionality may change before launch. For more information, visit www.pyxwallets.com.

What Comes Next

When the change of control closes, PYX would become the control person of GBHL and appoint the Company’s officers and directors.

The parties have agreed to use their best efforts to complete audited financial statements for the combined company and file a registration statement with the SEC within 90 days after the change of control. Once the registration statement is effective, the Company may raise additional capital to support the launch of PYX’s products.

“People carry their cards every day, while more of their financial lives are becoming digital. We believe their wallet should evolve with them,” said Ryan Contardi, Chief Executive Officer of PYX Wallets. “We are building PYX around that idea, combining a premium look and feel with technology that puts control of the wallet in its owner’s hands. Whether people want smarter protection for everyday cards or the option to bring physical cards and digital assets together, PYX is designed to make their wallet work on their terms.”

“When the court appointed a custodian, GBHL had been abandoned by its former management and had no operations,” said Richard C. Hawkins, Chief Executive Officer of GBHL. “We rebuilt it with the support from the court through the custodianship process and with full disclosure so shareholders would have a clean company to build on. PYX brings a new business and product line to that foundation. Now the work is to hit each milestone, starting with the audit and filing with the SEC.”

Court Custodianship

The Agreement is the first strategic transaction for GBHL since its restoration. The Company’s former management abandoned it in 2023, leaving it with no operations.

In May 2025, the Eighth Judicial District Court of Nevada appointed a custodian. The custodian reinstated the Company with the Nevada Secretary of State, appointed interim officers and directors, and ran a court-supervised creditor-notice process. In March 2026, the Court entered an order barring unasserted claims. On September 28, 2026, stockholders ratified the custodian’s actions, elected new management and approved the cancellation of 3,702,000,000 shares issued under a rescinded 2023 share exchange. The custodian has since filed a motion asking the Court to discharge the custodianship and enter a final order, which is pending.

The cleanup is reflected on the balance sheet. Total reported liabilities fell from approximately $856,000 at December 31, 2025 to approximately $384,000 at September 30, 2026, after the Company recognized a gain of approximately $494,000 on liabilities barred by the court order.

About PYX Wallets

PYX Wallets Inc. is a Delaware corporation developing titanium smart wallets that combine fingerprint access, physical card protection and connected app controls. PyX Core is designed for everyday card security. PyX Vault combines Core’s connected security features with a hardware crypto wallet, keeping private keys offline and providing on-device transaction review and approval. For more information, visit www.pyxwallets.com.

About Global Entertainment Holdings, Inc.

Global Entertainment Holdings, Inc. is a Nevada corporation quoted on OTC Markets under the symbol “GBHL.” Following a court-supervised custodianship, the Company is pursuing a strategic transaction to establish new operations.

Investor Contact
info@gbhlinc.com | +1 480-788-7420

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the proposed change of control under the letter of intent, the execution of definitive agreements, the transfer of voting and board control, PYX vending its business into the Company, the discharge of the custodianship, financing plans, reporting status, the completion of audited financial statements and the filing of a registration statement, and the development, features and launch of PYX’s products. Forward-looking statements can be identified by words such as “would,” “intends,” “contemplates,” “anticipates,” “plans,” “expects” and similar expressions.

These statements are based on current expectations and are subject to significant risks and uncertainties, including: that the letter of intent may be terminated under its terms, including if definitive agreements are not executed within 30 days, with certain obligations surviving; that definitive agreements may not be executed or the change of control may not be completed; that the Court may not enter a final order discharging the custodianship when expected or at all; that the required audit and registration statement may not be completed within the contemplated time frame or at all; that PYX’s products are in development and may not be completed, manufactured or launched on the expected timeline, at the expected cost or at all, and that their final design and features may change; that PYX’s products may not achieve market acceptance; that PYX may face competition from established wallet and hardware crypto-wallet makers; that the digital-asset features of PYX’s products may be affected by evolving laws and regulations; that additional funding may not be available on acceptable terms or at all; that securities remain subject to applicable former-shell-company resale restrictions under Rule 144(i); and that existing indebtedness and future financing may substantially dilute common stockholders. The super-voting preferred stock would concentrate voting control in PYX even if PYX’s common equity ownership is diluted.

The safe harbor for forward-looking statements provided by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 is not available to the Company. The Company undertakes no obligation to update any forward-looking statement except as required by law.

This press release is for informational purposes only. It does not constitute an offer to sell or the solicitation of an offer to buy any security, and there shall be no sale of any security in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering of securities will be made only in accordance with applicable law and, where applicable, pursuant to an effective registration statement or qualified offering statement and the delivery of a prospectus or offering circular.

Source: Global Entertainment Holdings, Inc.

CULVER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, today highlighted continued progress across its gaming portfolio, with an upcoming launch for Dead Party, positive early reception for The Fame Game II, three indie titles featured in Steam Next Fest, and expanded visibility for internally developed titles following IGN Fan Fest. Together, these milestones demonstrate continued activity across the Company’s publishing and development pipeline as it works to introduce new experiences to players and advance titles toward launch.

Dead Party sets October 29, 2026 launch date
Developed by Radiation Blue in collaboration with Snail Games USA, Dead Party is scheduled to launch on Steam on October 29, 2026. The four-player cooperative zombie survival game challenges players to work together to defend their neighborhood against waves of the undead. Its expanded Steam Next Fest demo lets players experience the cooperative gameplay ahead of launch, connecting the game’s current promotional activity with its upcoming commercial release.

The Fame Game II: LA Heartbreaker earns “Overwhelmingly Positive” Steam rating
Launched on Steam last week, The Fame Game II: LA Heartbreaker received a “Very Positive” rating at launch and an “Overwhelmingly Positive” rating to date, with more than 500 reviews. The early reception marks an encouraging milestone for the title and adds to the range of activities across the Interactive Films portfolio.

Expanding player engagement and visibility through Steam Next Fest and IGN Fan Fest
Snail Games is participating in this week’s Steam Next Fest with new demos for Dead Party, Whispers of West Grove, and Veil of Madness. The showcase allows players to experience the titles firsthand while increasing their visibility on Steam. By bringing multiple titles to the festival, Snail Games continues to build awareness across its portfolio and create opportunities for players to discover upcoming releases.

Last week, Snail Games participated in IGN Fan Fest, providing additional insight into For the Stars, its open-world science-fiction survival title, and 9 Yin Sutra: Immortal, a fantasy open-world experience. The showcase offered another opportunity to introduce these projects to gaming audiences and highlight the breadth of the Company’s development pipeline beyond its current publishing releases.

Learn more about the presence of 9 Yin Sutra: Immortal and For The Stars at IGN FanFest below:
Watch 9 Yin Sutra: Immortal IGN FanFest Trailer
Read For The Stars IGN FanFest Article + Exclusive New Images

As Snail Games continues to advance through the quarter, the Company remains focused on supporting upcoming releases, strengthening player awareness, and developing original experiences.

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. These forward-looking statements include information about possible or assumed future results of Snail Games’ business, financial condition, results of operations, liquidity, plans and objectives. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding the milestones demonstrating continued activity across the company’s publishing and development pipeline as it works to introduce new experiences to players and advance titles toward the market; Snail continuing to build awareness across its portfolio and creating opportunities for players to discover upcoming releases; and Dead Party being scheduled to launch on Steam on October 29, 2026; Further information on risks, uncertainties and other factors that could affect Snail Games’ financial results and business is included in its filings with the Securities and Exchange Commission (the “SEC”) from time to time, including its ability to continue to build awareness across its portfolio and publish and develop a pipeline that is attractive to players and the other risk factors set forth in its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q filed, or to be filed, with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those expressed or implied in the forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on management’s beliefs and assumptions and on information currently available to Snail Games, and Snail Games does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
SNAL@gateway-grp.com

— Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy —

— Second preclinical study shows inhibitory effects of sotagliflozin on platelet activity and thrombus formation —

— Findings underscore differentiated biology associated with dual SGLT1 and SGLT 2 inhibition —

THE WOODLANDS, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today highlighted findings from two newly reported preclinical studies that provide additional insight into the biological effects of sotagliflozin, Lexicon’s first-in-class dual SGLT1 and SGLT2 inhibitor. The investigator-initiated studies, funded by Lexicon and conducted by independent academic investigators, demonstrated favorable effects of sotagliflozin on key pathways involved in hypertrophic cardiomyopathy (HCM) and thrombotic cardiovascular events.

The first study, published in the Journal of Molecular and Cellular Cardiology Plus¹, found that sotagliflozin improved cardiac structure and function in a mouse model of hypertrophic cardiomyopathy, while reducing oxidative stress and upregulating mitochondrial gene sets associated with energy production in myocardial tissues. Investigators reported that sotagliflozin normalized measures of diastolic function, reversed progression of cardiac hypertrophy and reduced cardiac fibrosis, findings that support further evaluation of its potential in HCM.

The second study, published in the Journal of Clinical Investigation², demonstrated that sotagliflozin, but not the selective SGLT2 inhibitor empagliflozin, reduced platelet activation and thrombus formation in ex vivo human blood and animal models, including an SGLT1 gene murine knockout model, without adversely affecting normal hemostasis. These findings provide additional insight into the differentiated biology of dual SGLT1 and SGLT2 inhibition and may provide support for previously observed reductions in myocardial infarction and stroke risk associated with sotagliflozin in heart failure and Type 2 diabetes clinical studies

“These studies add to a growing body of evidence demonstrating the broad biological effects of sotagliflozin across multiple pathways relevant to cardiovascular disease,” said Craig Granowitz, M.D., Ph.D., senior vice president and chief medical officer of Lexicon. “From cardiac remodeling and mitochondrial function to platelet activation and thrombosis, the findings continue to expand our understanding of the differentiated biology associated with dual SGLT1 and SGLT2 inhibition and further support the scientific rationale for evaluating sotagliflozin in areas of significant unmet need, including hypertrophic cardiomyopathy.”

Lexicon is currently evaluating sotagliflozin in the ongoing Phase 3 SONATA-HCM trial in patients with symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy. Topline results are expected in the first quarter of 2027.

About Sotagliflozin
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients. Sotagliflozin is also currently under investigation for hypertrophic cardiomyopathy (HCM).

About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company pursuing novel medicines for patients with serious cardiometabolic diseases. Building on a proven legacy in genetic target discovery, Lexicon is advancing a clinical pipeline in areas of significant and often underserved need, with programs in hypertrophic cardiomyopathy (HCM), type 1 diabetes (T1D), obesity and other related metabolic conditions. Lexicon is committed to developing differentiated therapies that can be integrated broadly into clinical practice, with the goal of expanding treatment options for patients. Its capabilities extend from early-stage target discovery through clinical development and commercialization, strategically paired with high-impact collaborations to maximize the global reach of its medicines.

For additional information, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to the research, development and therapeutic and commercial potential of sotagliflozin in hypertrophic cardiomyopathy. In addition, this press release may also contain forward-looking statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

¹ Qin F, et al. Sotagliflozin corrects myocardial phenotype, mitochondrial gene expression and oxidative stress in mice with hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology Plus. 2026;100873. doi:10.1016/j.jmccpl.2026.100873.

² Stanger L, et al. SGLT1/2 inhibitor sotagliflozin, but not SGLT2-selective inhibitor empagliflozin, attenuates platelet activation and thrombosis. Journal of Clinical Investigation. 2026. In-Press Preview. doi:10.1172/JCI201899.

With the remaining 39% ownership of Demora Foundation, consolidating 100% ownership of its institutional blockchain infrastructure, JP3E advances the K2Global SMB 500 initiative

TRENTON, N.J. and SEOUL, South Korea, Oct. 21, 2026 (GLOBE NEWSWIRE) — JP3E Holdings Inc. (OTC: JPTE) (“JP3E” or the “Company”) today announced the completion of its acquisition of the remaining 39% ownership interest in Demora Foundation, increasing its total ownership from 61% to 100%.

As a result of the transaction, Demora Foundation is now a wholly owned subsidiary of JP3E Holdings Inc., consolidating the Company’s ownership and strategic control over its blockchain infrastructure, institutional Real-World Asset (RWA) tokenization initiatives, and digital asset settlement capabilities.

The acquisition represents a significant milestone in JP3E’s strategy to develop an integrated global financial infrastructure connecting real-world assets, blockchain technology, institutional capital, and international business development.

Completion of Strategic Acquisition

On March 20, 2026, JP3E Holdings announced the acquisition of a 61% controlling ownership interest in Demora Foundation as part of a strategic transaction involving Mammoth Labs Inc.

The initial acquisition established Demora Foundation as the blockchain infrastructure supporting JP3E’s K2Global SMB 500 initiative, an international business development program designed to connect 500 Korean small and medium-sized enterprises with U.S. capital markets and global business opportunities.

With the acquisition of the remaining 39% ownership interest, JP3E Holdings Inc. has consolidated 100% ownership of Demora Foundation.

The completed acquisition strengthens JP3E’s ability to direct the Foundation’s technology development, corporate governance, institutional partnerships, and commercialization strategy.

Full ownership is expected to enhance operational coordination and provide the Company with greater flexibility to execute its long-term blockchain and institutional digital asset strategy.

Expanding Institutional RWA Tokenization Infrastructure

Demora Foundation serves as a core component of JP3E’s strategy to develop institutional blockchain infrastructure supporting the tokenization, management, and settlement of real-world assets.

The Company’s long-term vision is to connect traditional asset markets with blockchain-enabled financial infrastructure, creating opportunities for greater transparency, efficiency, and accessibility in institutional finance.

The Foundation’s strategic development priorities include:

Real-World Asset Tokenization: Development of blockchain-based financial instruments associated with eligible physical assets, including infrastructure, real estate, commodities, energy, and industrial assets.

Institutional Blockchain Infrastructure: Technology designed to support asset registration, ownership records, transaction transparency, and digital asset management.

Digital Asset Settlement: Development of blockchain-enabled settlement mechanisms intended to improve transaction efficiency, traceability, and operational transparency.

Governance and Compliance: Establishment of appropriate technology governance, asset verification procedures, and compliance-oriented operating frameworks.

Global Capital Market Integration: Connecting eligible tokenized assets and investment opportunities with financial institutions, qualified investors, and international capital markets, subject to applicable regulatory requirements.

Through full ownership of Demora Foundation, JP3E intends to accelerate the development and commercialization of these capabilities within its broader corporate ecosystem.

Advancing the K2Global SMB 500 Initiative

Demora Foundation will continue serving as the blockchain infrastructure supporting JP3E’s K2Global SMB 500 initiative.

The initiative is designed to connect 500 Korean small and medium-sized businesses with U.S. business opportunities, institutional financing, and international capital markets.

K2Global focuses on businesses operating in strategic and high-growth industries, including advanced manufacturing, artificial intelligence, biotechnology, energy, critical materials, food, beauty, and cultural industries.

JP3E intends to leverage Demora Foundation’s blockchain technology to support innovative financing models, asset-backed digital financial instruments, and cross-border investment infrastructure.

The initiative also aligns with JP3E’s broader Innovation K-Wave Cities development strategy, which seeks to establish international business and technology ecosystems in major U.S. markets, including New York, Atlanta, and Dallas.

By combining institutional blockchain infrastructure with international business development, JP3E aims to expand opportunities for participating businesses while strengthening economic cooperation between the United States and South Korea.

Management Commentary

John K. Park, Chairman and Chief Executive Officer of JP3E Holdings Inc., stated:

“Completing the acquisition of 100% of Demora Foundation marks an important milestone in JP3E Holdings’ transformation into a global blockchain and digital financial infrastructure company.

Our initial acquisition established strategic control of Demora Foundation. With full ownership, we now have the opportunity to integrate its institutional RWA tokenization infrastructure more closely with our long-term business development and capital market initiatives.

We believe that blockchain technology and the tokenization of real-world assets will play an increasingly important role in connecting traditional industries with global institutional capital.

Through Demora Foundation and our K2Global SMB 50o initiative, we intend to create an innovative financial ecosystem that supports international business expansion, capital formation, and long-term economic development.

Full ownership of Demora Foundation strengthens our corporate governance, enhances strategic flexibility, and positions JP3E to pursue sustainable growth and long-term shareholder value.”

Corporate Ownership and Strategic Structure

Following completion of the acquisition, JP3E’s relevant corporate and strategic structure is as follows:

Entity / Initiative	Ownership / Relationship
JP3E Holdings Inc. (OTC: JPTE)	Parent Company
Demora Foundation	100% wholly owned by JP3E Holdings Inc.
K2Global SMB 500	Strategic business development initiative

The acquisition consolidates ownership of Demora Foundation, establishing a unified framework for technology development, corporate governance, institutional partnerships, and international business initiatives.

Long-Term Strategic Vision

JP3E intends to position Demora Foundation as a foundational technology asset within the Company’s expanding digital financial infrastructure ecosystem.

The Company’s strategic priorities include expanding institutional RWA tokenization capabilities, strengthening relationships with financial institutions and technology partners, supporting global business development, and creating additional opportunities for blockchain-enabled capital formation.

Through the integration of Demora Foundation’s infrastructure with the K2Global initiative, JP3E aims to establish a scalable platform connecting traditional industries, emerging technologies, and institutional financial markets.

The Company believes that full ownership of Demora Foundation will support the execution of these initiatives and strengthen JP3E’s long-term competitive position.

About Demora Foundation

Demora Foundation is a blockchain infrastructure and governance organization focused on institutional Real-World Asset (RWA) tokenization, digital asset management, and blockchain-based financial applications.

As a 100% wholly owned subsidiary of JP3E Holdings Inc. (OTC: JPTE), Demora Foundation serves as a strategic technology infrastructure component supporting institutional RWA tokenization, digital settlement, and the K2Global SMB 500 initiative.

Official Website: www.demora.foundation

About JP3E Holdings Inc.

JP3E Holdings Inc. (OTC: JPTE) is a U.S.-based holding company focused on strategic investments and business development across blockchain infrastructure, institutional digital assets, advanced technologies, global capital markets, and international economic development.

Through its K2Global initiative and strategic business activities, JP3E seeks to connect emerging technologies, innovative businesses, and institutional investment opportunities across the United States and international markets.

Official Website: www.jp3e.com

Corporate Contact:

JP3E Holdings Inc.
John K. Park
Chairman & Chief Executive Officer

1300 Kuser Road, First Floor
Trenton, NJ 08619, USA

MEDIA & INVESTOR CONTACTS

JP3E Holdings, Inc.
Email: info@jp3e.com

Website: https://jp3e.com/ · www.jp3eholdings.com X: x.com/JP3EHoldingsInc · Facebook: facebook.com/JP3E Holdings Inc

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws.

Forward-looking statements include statements concerning the Company’s strategic objectives, blockchain infrastructure development, RWA tokenization initiatives, institutional partnerships, international business development, capital market opportunities, and anticipated future growth.

These statements reflect current management expectations and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied.

Such risks may include regulatory developments, technology adoption, market conditions, financing availability, operational challenges, and the Company’s ability to successfully implement its business strategies.

JP3E Holdings Inc. undertakes no obligation to update or revise any forward-looking statement except as required by applicable law.

Shareholder Special Meeting Scheduled for November 19, 2026

• Definitive proxy statement filed with the SEC, marking an important milestone toward completion of the proposed transaction
• HeartSciences Board of Directors unanimously recommends shareholders vote FOR the transaction-related proposals
• Proposed combination expected to establish a publicly traded, vertically-integrated digital asset mining platform focused on Zcash, subject to shareholder approval and other closing conditions

SOUTHLAKE, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology company, today announced that it has filed its definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with its previously announced proposed business combination with Fortitude Mining Holdings, Inc. (“Fortitude”), a vertically-integrated digital asset mining platform anchored in Zcash (the “Proposed Transaction”).

The filing of the Definitive Proxy Statement represents an important milestone toward completing the Proposed Transaction, which was initially announced on June 23, 2026.

HeartSciences has scheduled a Special Meeting of Shareholders for November 19, 2026, at 10:00 a.m. Eastern Time, to consider and vote upon the Proposed Transaction and related proposals. Shareholders of record as of October 8, 2026, are entitled to vote at the meeting.

The HeartSciences Board of Directors has unanimously approved the transaction-related proposals and recommends that shareholders vote FOR each proposal, as more fully described in the Definitive Proxy Statement.

Proposed Business Combination

Under the terms of the definitive merger agreement, HeartSciences and Fortitude have agreed to combine in an all-stock transaction.

Upon completion of the Proposed Transaction, the combined company is expected to operate under the Fortitude brand, with its Class A common stock expected to trade on Nasdaq under the ticker symbol “TUDE,” subject to applicable listing requirements and Nasdaq approval.

Fortitude operates an institutional-scale, vertically-integrated digital asset mining platform, combining mining operations, data center infrastructure, and power assets, with a strategic focus on Zcash.

Completion of the Proposed Transaction remains subject to HeartSciences shareholder approval, applicable Nasdaq listing requirements and other customary closing conditions.

Special Meeting and Shareholder Voting

The Special Meeting will be conducted virtually on November 19, 2026, at 10:00 a.m. Eastern Time.

Shareholders may access the meeting at: https://edge.media-server.com/mmc/p/ztcy99wt The Definitive Proxy Statement and accompanying proxy materials are being distributed to eligible shareholders and provide information regarding the Proposed Transaction, the proposals to be voted upon, voting procedures and other relevant matters.

Eligible shareholders are encouraged to carefully review the Definitive Proxy Statement and submit their votes promptly, whether or not they intend to participate in the Special Meeting.

Registered shareholders may vote in advance through the procedures described in their proxy materials, including online at www.voteproxy.com. Shareholders holding shares through banks, brokers or other nominees should follow the instructions provided on their voting instruction form.

If you have any questions or need assistance voting your shares, please contact our proxy solicitor, Okapi Partners LLC, at:

1212 Avenue of the Americas, 17^th Floor
New York, NY 10036
Toll-Free: (855) 208-8902
or
E-mail: info@okapipartners.com

The Definitive Proxy Statement is available free of charge through the SEC’s website at www.sec.gov, linked for ease of access here.

Additional Information About the Proposed Transaction and Where to Find It

This press release constitutes a communication in connection with the Proposed Transaction and may be deemed solicitation material in respect of the Proposed Transaction.

On October 19, 2026, HeartSciences filed the Definitive Proxy Statement with the SEC and may file additional relevant materials with the SEC from time to time. HeartSciences is mailing the Definitive Proxy Statement and a proxy card to shareholders entitled to vote at the Special Meeting relating to the Proposed Transaction.

INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO, AND ALL OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES, FORTITUDE AND THE PROPOSED TRANSACTION.

This press release does not contain all the information that should be considered concerning the Proposed Transaction and related matters and is not intended to provide the basis for any investment decision or other decision concerning such matters.

Investors and shareholders may obtain copies of the Definitive Proxy Statement and other relevant filings free of charge at www.sec.gov or by submitting a request to HeartSciences Investor Relations at investorrelations@heartsciences.com.

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements concerning HeartSciences, Fortitude, the Proposed Transaction and other matters.

Forward-looking statements may be identified by terms such as “anticipate,” “expect,” “plan,” “will,” “would,” “believe,” “estimate,” “goal,” “intend,” and similar expressions. Statements other than historical facts should be considered forward-looking statements.

These statements include, without limitation, expectations regarding the timing and completion of the Proposed Transaction, the anticipated benefits of the Proposed Transaction, the future operations and strategy of the combined company, and the expected Nasdaq listing and trading symbol.

Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties and other factors that could cause actual outcomes to differ materially from those expressed or implied.

These risks include, among others:

• The possibility that the Proposed Transaction may not be completed on the anticipated timeline or at all;
• Failure to satisfy closing conditions, including obtaining the necessary HeartSciences shareholder approvals and applicable Nasdaq listing approvals;
• Market, macroeconomic and business conditions affecting HeartSciences, Fortitude or the combined company;
• Risks associated with integrating operations and managing a newly public company;
• Risks related to Fortitude’s mining operations, including the substantial volatility of Zcash and other digital asset prices; and
• Legal, commercial, regulatory and technical uncertainties associated with digital assets.

Additional risks and uncertainties are described in the Definitive Proxy Statement, HeartSciences’ Annual Report on Form 10-K filed July 23, 2026, its Quarterly Report on Form 10-Q filed September 14, 2026, and other SEC filings.

Readers are cautioned not to place undue reliance on forward-looking statements. HeartSciences and Fortitude undertake no obligation to update or revise forward-looking statements except as required by applicable law. All forward-looking statements speak only as of the date of this release.

Participants in the Solicitation

HeartSciences and Fortitude, their respective directors and executive officers, and certain executive officers of Digital Currency Group (“DCG”) , Fortitude’s parent company, may be deemed participants in the solicitation of proxies from HeartSciences shareholders in connection with the Proposed Transaction.

Information regarding these participants and their direct or indirect interests in the Proposed Transaction, whether through securities holdings or otherwise, is described in the Definitive Proxy Statement and other relevant SEC filings.

About Fortitude

Fortitude, currently wholly owned by DCG, is an institutional-scale, vertically-integrated venture mining platform operating across the Proof-of-Work ecosystem and anchored in Zcash. Fortitude pairs self-mining operations with an owned data center footprint, a diversified power portfolio backed by competitive long-term contracts, and disciplined capital allocation to identify and scale high-conviction opportunities in emerging Proof-of-Work ecosystems, beginning with its leadership position in the Zcash network. Fortitude is led by an experienced team of operators, capital markets professionals, and digital asset specialists with a track record of identifying and scaling high-conviction opportunities and building privacy-preserving digital asset infrastructure.

For more information, visit www.fortitudemining.com and follow Fortitude on X at @FortitudeCrypto

In the ordinary course of business, Fortitude currently sells or otherwise monetizes all the digital assets that it mines, including ZEC. In addition, Fortitude and its affiliates and subsidiaries, including DCG, from time to time sell, pledge or otherwise monetize their digital asset holdings, including ZEC. The funds received from such sales, pledges, or other monetization activities are used to fund operating expenses and capital investments, as well as for other purposes, including to hedge exposures and realize investment gains.

About HeartSciences Inc.

HeartSciences is a healthcare information technology company advancing the use of electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence. HeartSciences’ MyoVista Insights™ platform is a device-agnostic ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting AI-enabled solutions.

For more information, visit www.heartsciences.com

Investor Relations Contact
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us 

Email: investorrelations@heartsciences.com

Fortitude Investor Relations and Media Contact:
ICR
Phone: 917-375-9457
Email: IR@fortitudemining.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dd7e1d4a-bc27-4a05-baa5-902736cdec1b

Nearly one in three adults who were still smoking or vaping after a prior ORCA trial had quit at the end of a year of cytisinicline treatment, with quit rates rising through the year

Among the participants new to cytisinicline (prior attempt on placebo), 39% had quit at the end of the year

Participants were in their mid-fifties on average, ranging up to age 79, and many had a history of chronic conditions; the typical participant who smoked had made five quit attempts before ORCA-OL, and every participant chose to try again

SEATTLE and VANCOUVER, British Columbia, Oct. 21, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced positive 52-week efficacy results from its long-term, open-label ORCA-OL clinical trial evaluating cytisinicline for cigarette smoking and e-cigarette cessation. The findings were presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona.

The ORCA-OL trial enrolled 479 adults, of whom 475 received at least one dose of cytisinicline 3 mg three times daily for up to 52 weeks and form the analysis population. Of these, 84.6% smoked cigarettes, 12.8% vaped exclusively, and 2.5% did both. This was a hard-to-treat population by design: every participant had already made a counseling-supported quit attempt in a prior ORCA trial (71% with cytisinicline), was still smoking or vaping, and chose to try again, and more than a third of those who smoked had also tried varenicline, bupropion, or both and were still smoking. People who smoked averaged 56 years of age and had smoked for an average of 37 years; many participants had a history of hypertension, depression, anxiety, cancer, or COPD, and 86% were taking other medications. Four-week sustained abstinence rates, the measure of quitting used in the trial, increased from 25.5% at Weeks 9–12 to 30.3% at Weeks 21–24 to 31.2% during the final four weeks of treatment (Weeks 49–52) in the total study population.

All of these are repeat-attempt results: the participants who smoked had made a median of five quit attempts before ORCA-OL, including their prior ORCA trial. Among participants who had received placebo in their prior trial and were still smoking or vaping, 26.3% had quit at Weeks 9–12 and 39.4% at Weeks 49–52. Among those who had already received cytisinicline in their prior trial and were still smoking or vaping, 27.8% had quit at Weeks 49–52. To the Company’s knowledge, ORCA-OL is the first year-long cessation study to include people who vape (73 participants), every one of them still vaping after a medically supported quit attempt. At the end of the year, in this repeat attempt, 32.8% of people who exclusively smoked and 24.6% of those who exclusively vaped had quit (31.2% overall).

“Most people need more than one attempt to quit, yet treatment beyond 12 weeks and retreatment had not previously been studied with cytisinicline,” said Mark Rubinstein, MD, Chief Medical Officer, Achieve. “These results provide the first data on extended treatment and retreatment with cytisinicline, and suggest that longer treatment of up to 52 weeks may help some people who smoke or vape sustain abstinence.”

“This is the first year-long treatment trial we know of in people who were still smoking or vaping after a medically supported quit attempt, and the people in it look like the patients clinicians see every day: older, on other medications, and living with chronic conditions, many having also tried other treatments and still smoking,” said Andrew D. Goldberg, MD, Chief Executive Officer, Achieve. “Every one of them chose to try again, and nearly a third were not smoking or vaping at the end of a year.”

The median duration of cytisinicline exposure was 361 days, with 69.7% (334/479 enrolled) of participants completing the 52-week study. The most common treatment-related adverse events were abnormal dreams (7.8%), insomnia (6.5%), and headache (3.8%); 3.6% of participants discontinued due to a treatment-related adverse event. Treatment-related nausea occurred in 1.5%. The independent Data Safety Monitoring Committee (DSMC) identified no new safety signals.

ORCA-OL was an open-label study designed to evaluate the long-term safety, tolerability, and efficacy of cytisinicline in adults who smoke cigarettes, use nicotine-containing e-cigarettes, or use both products. Participants received cytisinicline 3 mg three times daily alongside behavioral support for up to 52 weeks. Efficacy assessments included four-week sustained abstinence and seven-day point prevalence abstinence, providing insights into cessation outcomes during extended treatment.

Achieve has completed two Phase 3 clinical trials, ORCA-2 and ORCA-3, evaluating cytisinicline for smoking cessation, as well as the Phase 2 ORCA-V1 trial evaluating cytisinicline for vaping cessation. The ORCA-OL findings provide additional long-term clinical evidence supporting the potential role of cytisinicline in treating nicotine dependence.

About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Tobacco use is currently the leading cause of preventable death, responsible for more than seven million deaths worldwide and nearly half a million deaths in the United States annually.²^,³

In addition, there are nearly 18 million adults in the United States who use e-cigarettes, also known as vaping.¹ In 2025, approximately 1.4 million middle and high school students in the United States reported using e-cigarettes.⁴ There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded Achieve the Commissioner’s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need.

Cytisinicline is an investigational compound that binds to nicotinic receptors. It is being developed as an aid to smoking cessation treatment in adults and as an aid to nicotine e-cigarette cessation.

About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements regarding the ORCA-OL results and their interpretation, the potential of cytisinicline for extended treatment, retreatment, and smoking and vaping cessation, the timing and outcome of Achieve’s planned NDA resubmission for cytisinicline, the timing of any FDA decision, the potential benefits of cytisinicline, the potential market for cytisinicline, the Company’s commercialization plans and readiness. Achieve may not achieve its plans, projections, or other expectations and may not be able to successfully complete its NDA resubmission or obtain regulatory approval for cytisinicline on the anticipated timeline or at all. ORCA-OL was an open-label, uncontrolled study, and its results, including results in subgroups of participants, may not be predictive of results in controlled clinical trials or in clinical practice. These statements are based on management’s current expectations and beliefs and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those detailed in Achieve’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Achieve undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
media@achievelifesciences.com
425-686-1510

References
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.
²World Health Organization. WHO Report on the Global Tobacco Epidemic, 2025. Geneva: World Health Organization; 2025.
³U.S. Department of Health and Human Services. The Health Consequences of Smoking, 50 Years of Progress. A Report of the Surgeon General. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
⁴Eunice Park-Lee, Lauren M Dutra, Hannah Cowan, et al. Tobacco Product Use Among Middle and High School Students in the United States: National Youth Tobacco Survey, 2025, Nicotine & Tobacco Research, 2026; ntag116, doi.org/10.1093/ntr/ntag116.

Company Backlog Reaches Record Level Above $52 Million; Entire Backlog Expected to Convert to Revenue During the Remainder of FY2026 and Throughout FY2027

HAUPPAUGE, N.Y., Oct. 21, 2026 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (NASDAQ: AMPG, AMPGZ) (the “Company” or “AmpliTech”), a designer, developer, and manufacturer of advanced radio frequency (RF) microwave components, 5G communication systems, and quantum computing low-noise amplifiers (LNAs), today announced that its AmpliTech, Inc. division has received a $1.03 million follow-on purchase order for low-noise amplifiers from a Fortune 1000 satellite communications company.

The additional order increases the Company’s total backlog to a record level above $52 million. Based on current production plans and customer delivery schedules, the Company expects to fulfill this backlog during the remainder of fiscal 2026 and fiscal 2027.

“Following our recently announced record $21.7 million order, this repeat order highlights the continued contribution of our RF component business alongside our growing 5G operations,” said Fawad Maqbool, Founder and CEO of AmpliTech Group. “Our backlog now exceeds $52 million, and our priority is executing these orders efficiently and meeting our customers’ delivery requirements. We continue to pursue additional opportunities across our businesses while maintaining a disciplined approach to production and working capital.” Furthermore Mr. Maqbool continued, “Based on our current operating plan and projected cash requirements, we believe our existing cash resources are sufficient to fund planned operations through the end of fiscal 2027. The Company also announced that it has received all remaining technical documentation and design deliverables required under its amended asset purchase agreement with Titan Crest”.

The Company is now focused on translating the intellectual property acquired and developed independently over the past two years into additional revenue in 2026 and 2027 through repeat and new orders from TELUS and other major mobile network operators (MNOs). Drawing on its advanced radio portfolio and customization capabilities, the Company has also submitted responses to several large requests for proposals (RFPs).

About AmpliTech Group, Inc.

AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGZ) is a designer, developer, and manufacturer of advanced RF and microwave signal processing components and next-generation 5G infrastructure systems. The company’s product portfolio spans low noise amplifiers, cryogenic amplifiers, Massive MIMO O-RAN radio systems, and 5G Network-in-a-Box solutions, serving customers across defense, satellite communications, quantum computing, and telecommunications. AmpliTech is the only American company to have designed and commercialized an O-RAN CAT B 64T64R Massive MIMO radio unit. All products are designed and engineered in the United States. For more information, visit www.amplitechgroup.com

Safe Harbor Statement

This release contains statements that constitute forward-looking statements. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things, that this follow on order will have any effect on the current pricing of the AMPG publicly traded shares and Rights. Any additional orders beyond those announced today remain subject to definitive purchase orders, customer deployment schedules and other customary conditions. The words “may” “would” “will” “expect” “estimate” “anticipate” “believe” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward- looking statements because of various factors. Other risks are identified and described in more detail in the “Risk Factors” section of the Company’s filings with the SEC, which are available on our website and with the SEC at sec.gov. We undertake no obligation to update, and we do not have a policy of updating or revising these forward-looking statements, except as required by applicable law.

Contacts:

Corporate Social Media
LinkedIn: AmpliTech Group, Inc.

Company Contact:
Jorge Flores
Tel: 631-521-7831
Investors@amplitechgroup.com

Latest 2300 V, 8 mΩ full-bridge SiCPAK™ G power module leverages proprietary GeneSiC™ Trench-Assisted Planar™ technology to deliver the industry’s leading R_DSON, enabling higher and power density for solid-state transformers, grid-scale battery energy storage systems, solar inverters, and megawatt charging infrastructure

TORRANCE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) — Navitas Semiconductor (Nasdaq: NVTS), a leader in next-generation power semiconductors and power delivery solutions, pioneering GaN, high-voltage and ultra-high-voltage SiC, and IVR technologies, today announced an ultra-high-voltage (UHV) SiC power module family for advanced energy and grid infrastructure.

The new G4H08MT23GB4 2300 V full-bridge module family uses the industry-standard SiCPAK™ form factor and has a class-leading R_DSON (8 mΩ).

It has been developed to enhance efficiency and power density in solid-state transformers, grid-scale battery energy storage systems, solar inverters, and EV megawatt charging infrastructure. These gains are enabled through its deployment of Navitas’ fourth-generation GeneSiC™ Trench-Assisted Planar™ (TAP) architecture, with the launch extending Navitas’ 2300 V and 3300 V ultra-high voltage SiC portfolio.

As grid-tied power architectures increasingly underpin next-generation AI data centers, Navitas’ UHV SiC modules provide the medium-voltage building block for solid-state transformers that convert grid power directly into the high-voltage DC rails used inside AI data center racks. This places the new module family at the center of Navitas’ AI infrastructure portfolio. spanning AI data center and energy and grid infrastructure alongside battery energy storage, solar, EV megawatt charging, hydrogen fuel cell electrolysis and DC-DC conversion, and industrial motor-drive and high-voltage power supply applications.

Advanced Construction for High-Reliability, High-Power Operation

The modules also integrate several construction enhancements that better meet the needs of demanding, high-power applications. For example, its aluminum nitride (AlN) active-metal-braze (AMB) substrate enables superior heat spreading and supports an isolation capability of over 5 kV. Its epoxy-resin potting technology reduces internal stress distribution, limits moisture and contaminant ingress, and delivers 10x improvements in thermal conductivity versus silicone gel.

Additionally, the module’s high-current, press-fit pins have twice the current-carrying capability per pin versus standard press-fit connections. An optional pre-applied thermal interface material (TIM), which simplifies and standardizes heatsink assembly, is also available.

Extended Reliability Testing Validates Long-Term System Lifetime

The new module family will be qualified to Navitas’ AEC-Plus* reliability benchmark, which tests beyond AEC-Q101 and JEDEC standard requirements. The benchmark reflects Navitas’ focus on system-level lifetime requirements for the demanding mission profiles found in energy and grid infrastructure applications.

The AEC-Plus qualification includes dynamic reverse bias (DRB) and dynamic gate switching (DGS) testing to represent stringent fast-switching application mission profiles; it also more than triples the duration of static high-temperature, high-voltage tests (HTRB, HTGB, HTGB-R). Additionally, it implements an extended power-cycling and temperature-cycling testing and delivers HV-H3TRB (HV-THB) qualification for power modules, discrete and known-good-die (KGD) devices.

“Our fourth-generation GeneSiC Trench-Assisted Planar architecture continues to push the limits of what’s possible in ultra-high voltage SiC,” said Paul Wheeler, VP & GM of Navitas’ SiC Business Unit. “This new 2300 V module delivers a leading RDS_(ON) of any device using the SiCPAK form factor, giving system designers a proven, reliability-tested building block for the solid-state transformers and energy storage systems that are reshaping grid and AI data center infrastructure.”

Samples of the G4H08MT23GB4(HC) family are available immediately, with options for pre-applied TIM and high-current variants:

Part Number	Configuration	Pre-Applied TIM	Pins
G4H08MT23GB4	Full-Bridge	No	Standard
G4H08MT23GB4-T	Full-Bridge	Yes	Standard
G4H08MT23GB4HC	Full-Bridge	No	High-Current
G4H08MT23GB4HC-T	Full-Bridge	Yes	High-Current

A double-pulse test (DPT) system, EVB-UHVSIC-GB-E-DPT-1, is also available on request. This has been created to help engineers evaluate the device’s switching performance. A white paper on Trench-Assisted Planar Technology is also available for download from the Navitas website.

To request samples, contact a Navitas representative or email info@navitassemi.com.

________________________________

*AEC-Plus is Navitas’ internal reliability qualification benchmark that extends beyond standard AEC-Q101 and JEDEC test requirements.

About Navitas
Navitas Semiconductor (Nasdaq: NVTS) is a leader in next-generation power semiconductors and power delivery solutions, pioneering GaN, high-voltage and ultra-high-voltage SiC, and IVR technologies for AI infrastructure, including data centers and energy and grid systems, as well as additional markets such as high-performance computing and industrial electrification. Collectively, these technologies address the complete grid-to-xPU power architecture, breaking the AI infrastructure power wall and enabling higher efficiency, greater power density, and increased performance across the entire power chain. Navitas’ GaNFast™ FETs deliver industry-leading power density, efficiency, and high-speed performance, while GaNFast™ power ICs integrate GaN power, drive, control, sensing, and protection to enable faster, more efficient power conversion, leading to smaller and more reliable systems. The GeneSiC™ portfolio combines proprietary trench-assisted planar (TAP) SiC technology with leading-edge discrete packaging and SiCPAK™ power modules to deliver industry-leading efficiency, ruggedness and performance. Claros™ IVR technologies extend power delivery directly to the xPU, enabling customers to implement vertical power delivery (VPD) and embedded power delivery (EPD) architectures with high-density power conversion beneath or within millimeters of the processor, minimizing power-delivery losses and impedance while enabling ultra-fast transient response, higher efficiency and maximum power density. Navitas has over 450 patents issued or pending and is a leader in 800 VDC and the advanced AI power infrastructure ecosystem.

Navitas^®, GaNFast^®, GeneSiC™, Claros™, SiCPAK^®, GaNSafe^®, DrGaN™, and the Navitas logo are trademarks or registered trademarks of Navitas Semiconductor Limited or affiliates. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are attempts to predict or indicate future events or trends or similar statements that are not a reflection of historical fact. Forward-looking statements may be identified by the use of words such as “we expect” or “are expected to be,” “estimate,” “plan,” “project,” “forecast,” “intend,” “anticipate,” “believe,” “seek,” or other similar expressions. Forward-looking statements are made based on estimates and forecasts of financial and performance metrics, projections of market opportunity and market share and current indications of customer interest, all of which are based on various assumptions, whether or not identified in this press release. All such statements are based on current expectations of the management of Navitas and are not predictions of actual future performance. Forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions and expectations. Many actual events and circumstances that affect performance are beyond the control of Navitas and, forward-looking statements are subject to a number of uncertainties. Our businesses are subject to certain risks that could materially and adversely affect our respective business, financial condition, results of operations, or the value of our securities. For Navitas, these and other risk factors are discussed in the Risk Factors section of our most recent annual report on Form 10-K, as updated in the Risk Factors section of our most recent quarterly report on Form 10-Q, and in other documents we file with the SEC. If any of these risks, as discussed in more detail in our SEC reports, materialize or if our assumptions underlying forward-looking statements prove to be incorrect, actual results could differ materially from the results implied by these forward-looking statements.

Contact Information
Navitas Semiconductor
Vipin Bothra
info@navitassemi.com

Navitas Investor Contacts
Leanne Sievers | Brett Perry
Shelton Group
sheltonir@sheltongroup.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2ce3de4e-67cd-43d7-863e-96c8cc93aa3b